Noticias y Actividades de Helsinn Healthcare
Ejecutivos
Ver el organigrama con sus 15 ejecutivos principales
Biografías más buscadas en Helsinn Healthcare
- Riccardo Braglia, Chief Executive Officer
- Paolo Bottini, Board Member
- Riccardo Carbucicchio, Executive Chairman of the Board
Recientes movimientos de ejecutivos en Helsinn Healthcare
- Melanie Rolli, Group Chief Executive Officer, ha dejado la empresa (noticia publicada el 13 de enero de 2026).
- Gabriele Braglia que ha sido Director, ha ascendido a Chief Business Officer and Deputy Chief Executive Officer (noticia publicada el 13 de enero de 2026).
- Riccardo Braglia que ha sido Board Member, ha ascendido a Chief Executive Officer (noticia publicada el 13 de enero de 2026).
Crear su alerta
para seguir los movimientos de los ejecutivos en Helsinn Healthcare.
Farmacia
Helsinn Healthcare tiene 1.913 competidores entre los que se incluyen Sanofi (Francia), Eli Lilly (Estados Unidos) y Moderna (Estados Unidos).
Popular M&A news in Farmacia
- Corden Pharma has announced the acquisition of AmbioPharm (publicado el 5 de junio de 2026).
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (publicado el 4 de junio de 2026).
- Contraline acaba de anunciar una recaudación de fondos de 93 millones de dólares. (publicado el 3 de junio de 2026).
Otros contactos sugeridos en el sector Farmacia
Noticias
Últimos comunicados de prensa de Helsinn Healthcare
- News - Helsinn
- News and Events - Helsinn
- https://www.helsinn.com/news-and-events/taiho-pharmaceutical-submits-new-drug-application-for-nk1-receptor-antagonist-fosnetupitant-for-prevention-of-gastrointestinal-symptoms-nausea-and-vomiting-associated-with-cancer-chemotherapy/
- https://www.helsinn.com/news-and-events/helsinn-publishes-prove-mf-ctcl-study-providing-new-data-for-mechlorethamine-gel-use-in-a-real-world-setting/
- Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety
- https://www.helsinn.com/news-and-events/announcement-of-approval-to-manufacture-and-market-5-ht3-serotonin-receptor-antagonist-antiemetic-agent-palonosetron-i-v-injection-palonosetron-i-v-infusion-bag-in-japan/
- ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan
- An interview with Dr. Larisa Geskin on an MF-CTCL fellowship at Columbia University supported by Helsinn
- Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities
- https://www.helsinn.com/news-and-events/helsinn-demonstrates-commitment-to-raising-awareness-on-cachexia-by-supporting-cachexia-societies-conferences/
- View more press releases Close
Redes sociales sobre Helsinn Healthcare
- Helsinn Healthcare en Wikipedia, Google News y Yahoo Finance
- Helsinn Healthcare en LinkedIn, Twitter y YouTube
